Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.57 |
| ▸ | CTSL | P07711 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 5/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903969 | 0.99 | CTSK (0.58) | CTSKCTSLCTSBCTSSITGB3 | |
| SCHEMBL4901597 | 0.98 | CTSK (0.57) | CTSKCTSLCTSBCTSSITGB3 | |
| SCHEMBL4897109 | 0.78 | CTSK (0.70) | CTSKCTSLCTSBCTSS | |
| SCHEMBL6645850 | 0.76 | CTSK (0.73) | CTSKCTSLCTSBCTSS | |
| SCHEMBL28086104 | 0.76 | ITGB3 (0.51) | CTSLCTSBCTSSITGB3ITGA2B | |
| SCHEMBL4908421 | 0.76 | NPC1 (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL6647428 | 0.76 | CTSK (0.74) | CTSKCTSLCTSBCTSS | |
| SCHEMBL4907308 | 0.76 | CTSK (0.72) | CTSKCTSLCTSBCTSS | |
| SCHEMBL4903966 | 0.75 | CTSK (0.72) | CTSKCTSLCTSBCTSS | |
| SCHEMBL5636392 | 0.74 | CTSK (0.73) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.